1158 results about "Methyl Donors" patented technology

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

The invention provides an UTR element NHP1 as well as a construction method and application thereof, and relates to the technical field of mRNA. A 5 'UTR with a good expression effect is designed by integrating dominant sequences of a human high-expression gene and a pathogen natural UTR, a chimeric structure NHP1 with high ribosome load is predicted through a calculation model, a DNA sequence of the NHP1 is as shown in SEQ NO 1, and an RNA sequence of the NHP1 is as shown in SEQ NO 2; an EGFP report system is adopted on the DNA level to rapidly screen UTR; the translation efficiency is quantitatively evaluated on the RNA level through luciferase mRNA (N1-methyl pseudouridine modification); and the particle size is controlled by a microfluidic technology, so that the optimized UTR-mRNA is efficiently expressed after being delivered.

The invention relates to a molecular marker related to the content of 2-acetyl-3-methylpyrazine in pig muscle and application of the molecular marker, belonging to the technical field of determination or inspection methods of enzymes, nucleic acids or microorganisms. The technical problem to be solved by the invention is to provide a molecular marker related to the content of 2-acetyl-3-methylpyrazine in pig muscle. In order to solve the technical problem, the molecular marker provided by the invention is obtained through genome-wide association (GWAS) analysis, the nucleotide sequence of the molecular marker is as shown in SEQ ID NO: 1, and the molecular marker has an Agt at the 6328556 position of a chromosome 9 of a pig genome; a nucleotide single base of G is mutated, and the mutation obviously affects the content of 2-acetyl-3-methylpyrazine in pig muscles. By detecting the genotype of a to-be-detected pig at the SNP site, early selection of the content of 2-acetyl-3-methylpyrazine in pig muscles can be realized.

The invention relates to hydrogel loaded with oxygen self-producing nanoparticles as well as a preparation method and application of the hydrogel. The preparation method comprises the following steps: 1, taking cross-linked methacrylamide silk fibroin and hyaluronic acid modified by arginine-glycine-aspartic acid peptide as base materials, and loading self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG, and the self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG are prepared by coating Cu-EGCG on calcium peroxide nano particles modified by PVP modified polyvinylpyrrolidone. The hydrogel can improve energy metabolism and regulate immune environment through dual mechanisms, realizes efficient promotion of myocardial repair, and provides a new strategy and thought for tissue regeneration and functional recovery after myocardial infarction.

The invention relates to a cartilage organ constructed on the basis of a DNA-silk fibroin hybrid hydrogel sustained-release system as well as a preparation method and application of the cartilage organ. The DNA-silk fibroin hybrid hydrogel sustained-release system is a hydrogel system formed by printing a DNA-silk fibroin hybrid hydrogel sustained-release system premix solution through a digital light processing system, and the DNA-silk fibroin hybrid hydrogel sustained-release system premix solution contains DNA, silk fibroin, acryloylated RGD peptide, acryloylated polyethylene glycol NHS ester, glucosamine, TD-198946 and 2, 4, 6-trimethyl-1, 3-pentanediol. The invention discloses a lithium 2, 6-trimethylbenzoyl phosphate. Compared with the prior art, the glucosamine and the TD-198946 introduced into the DNA-silk fibroin hybrid hydrogel sustained-release system disclosed by the invention can be used for remarkably improving and promoting the cartilage differentiation efficiency of the bone marrow mesenchymal stem cells; the cartilage graft can be transplanted to a cartilage defect position as a cartilage graft to promote cartilage regeneration and repair.

The invention discloses an ovarian protection composition containing ergothioneine and a preparation method of the ovarian protection composition, and relates to the technical field of ovarian protection compositions. The ovary protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.1 to 0.5 part of the ergothioneine, 0.05 to 1 part of S-equol, 1 to 5 parts of reducing coenzyme Q10, 1 to 3 parts of vitamin E, 10 to 20 parts of chitosan oligosaccharide, 30 to 50 parts of microcrystalline cellulose, 3 to 8 parts of hydroxypropyl methyl cellulose, 0.5 to 2 parts of silicon dioxide and 0.5 to 2 parts of a stabilizer. By adopting the stabilizer, photooxidation and hydrolysis of sensitive components are inhibited through molecular action, and the long-term stability of the composition in a humid and hot environment is remarkably improved in combination with the physical barrier action of silicon dioxide. Through the antioxidant synergistic effect of the ergothioneine and the vitamin E, the hormone regulation effect of the S-equol and the energy metabolism improvement effect of the coenzyme Q10, a multi-layer ovarian function protection system is constructed, and the health state of ovaries is improved. Through a special process, the tablet can be rapidly disintegrated and slowly released in an intestinal targeted manner, burst release of active ingredients is avoided, and the absorption efficiency is improved.

The invention belongs to the field of pharmaceutical analysis, and discloses a method for simultaneously determining the contents of tolperidone hydrochloride, methyl hesperidin and vitamin B6 in Naoluotong capsules, the method comprises three steps of preparation of a mixed reference solution, preparation of a test solution and content determination, and the chromatographic conditions of the content determination are as follows: a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column and a C18 chromatographic column; a mobile phase is methanol (A)-0.1% glacial acetic acid solution (B), gradient elution is carried out for 0-5 min, and 96% of B is obtained; 5-6 min, 96%-60% of B is selected; 6-20 min, the content of B is 60%-50%; the volume flow rate is 1.0 ml / min; the column temperature is 30 DEG C; the detection wavelength is 291 nm; the sample size is 1 microliter. According to the method, synchronous detection of three components (tolperidone hydrochloride, methyl hesperidin and vitamin B6) with remarkable physicochemical property difference can be realized, the chromatographic condition is simple, and the detection speed is high.

The invention discloses a preparation method of a sandwich structure immunosensor based on surface enhanced Raman scattering and application of the sandwich structure immunosensor to detection of an anti-phospholipase A2 receptor antibody, and is characterized by comprising the following steps: sputtering silver ions on a cotton swab / ZIF-67 prepared by an in-situ growth method by adopting an ion sputtering method to obtain a cotton swab / ZIF-67 / Ag NPs composite material; the preparation method comprises the following steps: preparing an antigen solution, then adding the antigen solution into the antigen solution to obtain an immune substrate, adding a methylene blue aqueous solution into a silver nanoparticle solution for reaction, then connecting an anti-human PLA2R IgG antibody to obtain an immune probe, and finally dropwise adding a phosphate buffer solution containing an antibody to be detected onto the immune substrate, and dropwise adding the immune probe solution to the immune substrate adsorbed with the antibody to be detected to obtain the sandwich structure immunosensor based on surface enhanced Raman scattering. The method has the advantages of high sensitivity, good selectivity and strong stability.

The invention belongs to the technical field of dressing preparation, and particularly relates to a preparation method of a photocuring methacrylated gelatin hydrogel dressing, which comprises the following steps: step 1, dissolving methacrylated gelatin in a phosphate buffer solution to prepare a methacrylated gelatin solution with the mass concentration of 5-15%; 2, adding a natural photoinitiator into the solution obtained in the step 1, and uniformly stirring and mixing; 3, adding the traditional Chinese medicine active ingredient powder, and stirring until the powder is uniformly dispersed to obtain a mixed solution; and 4, pouring the mixed solution into a mold, and curing and molding under the irradiation of visible light. Chlorophyll or riboflavin is used as a natural photoinitiator and is directly dispersed in a methacrylated gelatin solution in a physical blending mode, a curing light source enables chlorophyll to completely avoid a chemical initiator, meanwhile, the process is simplified into physical stirring to replace nanoparticle synthesis and modification, visible light reduces the risk of tissue burn, the production cost is reduced, and the method is suitable for industrial production. The method is suitable for primary medicine.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The present invention relates to solid forms of the poly(ADP-ribose) polymerase 7 (PARP7) inhibitor 5-[[(2S)-1-(3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy)propan-2-yl]amino]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one, and salts thereof, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer.

The invention relates to the technical field of biomedical dressings, in particular to a dressing for a diabetic foot wound surface and a preparation method of the dressing. 0.2 to 0.8 part of reduced graphene oxide; 2 to 5 parts of beta-1, 3-glucan modified by chondroitin sulfate; 0.08 to 0.3 part of silver nitrate; 3 to 7 parts of N-isopropyl acrylamide-co-acrylic acid; 0.15 to 0.4 part of N, N '-methylene bisacrylamide; 2 to 5 parts of sulfhydrylated hyaluronic acid; 0.3 to 0.8 part of D-alpha-vitamin E polyethylene glycol succinate; 2 to 5 parts of amino-functionalized mesoporous silica; 1 to 3 parts of L-arginine-L-glutamate; 0.1 to 0.4 part of genipin; the super-strong mechanical property and the super-strong flexibility are realized, so that the dressing can better adapt to the irregular shape of a wound surface, and continuous protection is provided.

The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-TH-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The invention belongs to the technical field of polyether refining, and particularly relates to a methyl-terminated polyether refining treatment method. Comprising the following steps: adding water into a to-be-refined methyl-terminated polyether sample, stirring, dissolving salt in water, layering, adding water into a polyether layer again after separation, stirring, layering, and separating to obtain a primary sample; taking a methyl-terminated polyether sample to be refined again, heating, adding water, adjusting the pH with acid, and stirring to obtain a sample A; adding the preliminary sample into the sample A, and stirring to obtain a sample B; and adding acid into the sample B to adjust the pH value, continuously stirring, crystallizing the metal salt into large particles, settling, separating out solids, deacidifying and decolorizing, dehydrating in vacuum, and filtering to obtain qualified methyl-terminated polyether products, and intercepting part of qualified products as preliminary samples for continuous production. By adding the methyl-terminated polyether primary finished product, the crystallization process of the metal salt can be effectively improved, so that the metal salt tends to generate coarse particles easy to filter, the filtering resistance is reduced, and the filtering period is shortened.

The invention relates to a high-water-solubility denitroflavin covalent complex as well as a preparation method and application thereof, and belongs to the technical field of organic synthesis and medicinal chemistry. Comprising the following steps: (1) firstly, carrying out bromination reaction on 3-methyl-10-ethyl denitroflavin, so as to obtain 3-methyl-10-(1-bromoethyl) denitroflavin; and (2) coupling the 3-methyl-10-(1-bromoethyl) denitroflavin with vitamin C, so as to obtain the high-water-solubility denitroflavin covalent complex. According to the present invention, the prepared highly water-soluble denitrificin covalent complex has the two-phase solubility of the organic solvent and the water, such that the water solubility of the 3-methyl-10-ethyl-denitrificin is substantially enhanced, and the application range of the denitrificin is expanded. And meanwhile, the denitrified flavin covalent compound also has good antioxidant activity, and the antioxidant duration can be prolonged.

Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of biological detection, and particularly relates to a method for synchronously and quantitatively detecting various folic acid metabolism related substances in trace plasma or serum, which comprises the following steps of: detecting a pretreated trace plasma or serum sample by adopting a liquid chromatography-tandem mass spectrometry method; the following nine folic acid metabolism related substances are synchronously and quantitatively detected: 5-formyl tetrahydrofolic acid, folic acid, 5-methyl tetrahydrofolic acid, S-adenosine-L-methionine, S-adenosine-L-homocysteine, vitamin B12, pyridoxamine, pyridoxine and pyridoxal. The invention further relates to application of the detection method in related detection of child neurodevelopment. According to the detection method, only trace plasma or serum is used, methotrexate is used for replacing an expensive isotope internal standard for more economical detection, and nine folate metabolism related substances can be accurately quantified at the same time. Therefore, the detection method disclosed by the invention has important clinical significance and wide market application prospect.

Methods for treating patients with moderate-to-severe asthma comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

The invention discloses a photocuring microneedle with ginseng exosome loaded berberine, a preparation method of the photocuring microneedle and application of the photocuring microneedle to tissue repair. A ginseng exosome loaded berberine compound is prepared through a microfluidic technology; filling a needle cavity of a microneedle mold with a needle tip layer preparation solution containing the compound, methylacryloylated hyaluronic acid and methylacryloylated gelatin through a centrifugal method; covering a backing layer preparation solution composed of hyaluronic acid and povidone K90, and centrifuging again; and finally, carrying out light curing, drying and demolding. The prepared composite microneedle is complete and sharp in needle shape and high in forming rate; the efficient entrapment of the active medicine is realized; the biocompatibility is good, and the irritation is low; a cross-linked network structure formed by photocuring is beneficial to realizing controlled release of drugs, the targeted repair function of the ginseng exosome is combined with the hypoglycemic effect of berberine, and a new strategy and technical approach with a prospect are provided for painless, efficient and long-acting treatment of diabetes mellitus.

Methods are provided for treating or preventing colorectal cancer, related diseases, or symptoms of any of the foregoing, e.g., familial adenomatous polyposis (FAP), in subjects of 55 years or older. The methods include administering 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4, 7-dione or a pharmaceutically acceptable salt thereof.

In some aspects, the present disclosure pertains to systems for forming hydrogels that comprise (a) a radiopaque polyamino compound and (b) a reactive polymer comprising a plurality of hydrophilic polymer segments and a plurality of reactive moieties, wherein the reactive moieties are reactive with amino groups of the radiopaque polyamino compound, and wherein the radiopaque polyamino compound is produced by a method that comprises: (i) converting hydroxyl groups of a polyhydroxylated radiopaque compound to amino groups, (ii) converting vicinal diol groups (—CHOHCH2OH groups) of a polyhydroxylated radiopaque compound into hydroxyaminoethyl groups (—CHOHCH2NH2 groups), or (iii) converting vicinal diol groups of a polyhydroxylated radiopaque compound into aminomethyl groups (—CH2NH2 groups). In other aspects, the present disclosure pertains to hydrogels formed from such systems and to methods of treatment using such systems.

The invention relates to the technical field of biomedical materials, in particular to photo-thermal antibacterial healing-promoting hydrogel as well as a preparation method and application thereof. The preparation method of the hydrogel comprises the following steps: dispersing mesoporous polydopamine (MPDA) into a Tris-HCl solution, and then adding L-arginine to prepare L-MPDA; the preparation method comprises the following steps: fully dissolving 3-(aminomethyl) phenylboronic acid hydrochloride and 4-(4, 6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride into hyaluronic acid (HA), regulating the pH value to 6.5 by using alkali liquor to obtain phenylboronic acid modified hyaluronic acid mixed liquor, and dialyzing and freeze-drying to obtain HA-PBA. The preparation method comprises the following steps: dissolving metformin and purified L-MPDA in deionized water, sequentially adding purified HA-PBA and a polyvinyl alcohol (PVA) solution, and uniformly mixing to obtain the hydrogel. The hydrogel prepared by the invention has excellent hemostasis, antibacterial and adhesion properties. When the hydrogel is used as a hydrogel dressing for treating a diabetic wound surface, the healing speed of the diabetic wound surface can be effectively improved.

The present invention is directed to substituted 1-(1H-imidazol-1-yl)-3-methyl-2- phenylbutan-2-ol and 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phenylethan-1-ol compounds useful as agonists of 8-oxo-guanine DNA glycosylase (OGG1) in humans, as well as pharmaceutical compositions comprising them and methods of their use in treating diseases, including metabolic syndrome, obesity, fatty liver disease, dyslipidemia, insulin resistance, neurodegenerative disorders and cancers.

In the first aspect, the present disclosure provides a Lactoferrin polypeptide fragment, where the Lactoferrin polypeptide fragment has an amino acid sequence shown in SEQ ID NO: 1. In the second aspect, the present disclosure provides a preparation method of the Lactoferrin polypeptide fragment, including: protecting amino acids using a 9-fluorenylmethoxycarbonyl (Fmoc) protecting group, coupling the amino acids with a P-hydroxymethylphenoxymethyl polyethylene resin (HMP resin) in an order of cysteine, alanine, leucine, cysteine, glutamate, threonine, asparagine, aspartate, asparagine, phenylalanine, leucine, leucine, asparagine, and lysine, and separating the HMP resin to obtain a target Lactoferrin polypeptide fragment. In the third aspect, the present disclosure further provides an anti-Lactoferrin antibody prepared using the Lactoferrin polypeptide fragment, and use of the Lactoferrin polypeptide fragment in preparation of an anti-Lactoferrin flow cytometric antibody and in preparation of a Lactoferrin detection product.

The invention discloses a demethylase ODM gene for synthesizing benzylisoquinoline alkaloids and application thereof, the demethylase ODM gene is an ODM1 gene or an ODM2 gene, the nucleotide sequence of the CDS region of the ODM1 gene is shown as SEQ ID NO: 1, and the nucleotide sequence of the CDS region of the ODM2 gene is shown as SEQ ID NO: 2. Aiming at the current situation that the research basis of a key gene for synthesizing corydalmine in rhizoma corydalis is weak, the ODM1 gene for catalyzing tetrahydropalmatine demethylation to specifically generate corydalmine and tetrahydrojatrorrhizine and the ODM2 gene for specifically generating tetrahydrojatrorrhizine are cloned from rhizoma corydalis for the first time. An important theoretical basis is provided for producing the corydalmine by utilizing a synthetic biological method in the future, and the corydalmine mutant has a wide application prospect and a great economic value.

The invention discloses an electrochemical urine biopsy system for cathepsin B analysis and a detection method of the electrochemical urine biopsy system. The electrochemical urine biopsy system comprises gold nanoparticles AuNPs, a peptide-peptide nucleic acid PNA series probe and an electrochemical sensor. The peptide-peptide nucleic acid tandem probe is combined with gold nanoparticles through a mercaptan modified sequence to form a spherical nanostructure with the diameter of 15 nm, a polypeptide substrate sequence serves as a specific reaction substrate of cathepsin B, and PNA provides stability and a signal shielding function. The electrochemical sensor is based on a cutting enzyme-assisted DNAwalker mechanism, signal amplification is started through methylene blue MB release, and high-sensitivity detection of the released PNA probe is achieved. The system provided by the invention has the characteristics of high specificity, high sensitivity and rapid response, can realize quantitative analysis of cathepsin B through noninvasive urine biopsy, and provides a new technical means for early diagnosis and treatment monitoring of tumors.

Methods for treating patients with wAIHA comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

The invention discloses a urine microalbumin immunoturbidimetry kit and a detection method, and belongs to the technical field of biology. The invention relates to a urine microalbumin immunoturbidimetry kit, which comprises a reagent R1, a reagent R2, a reagent R3 and a reagent R4, wherein the reagent R1 comprises trihydroxymethyl aminomethane, a coagulant, a blocking agent, sodium chloride, bovine serum albumin, trehalose, a preservative and ultrapure water; the reagent R2 is prepared from hydroxyethyl piperazine ethanesulfonic acid, sodium chloride, bovine serum albumin, glycerol, trehalose, a preservative, a mALB monoclonal antibody and ultrapure water; the mALB monoclonal antibody is prepared by mixing a model number of UDA 9107-1, a model number of UDA 9107-2, a model number of UDA 9107-3 and a model number of UDA 9107-4 according to a mass ratio of (0.8 to 1.2): (0.8 to 1.2): (0.8 to 1.2): (0.8 to 1.2). A mixed antibody of four mALB monoclonal antibodies is specifically combined with a urine microalbumin antigen in a sample to form an antigen-antibody compound, and the antigen-antibody compound has high specificity and high sensitivity; the method has a relatively high detection range, can effectively avoid a hook effect of an ultrahigh-value sample, and can realize rapid and convenient automatic detection.